Maze Therapeutics Inc(MAZE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 3 at 4:01 PM ET (Korea 11/4 06:01)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.53 | Insider Own | 37.91% | Shs Outstand | 55.5M | Perf Week | 1.77% |
| Market Cap | 1.79B | Forward P/E | - | EPS next Y | -16.57% | Insider Trans | -1.85% | Shs Float | 34.5M | Perf Month | 22.02% |
| Enterprise Value | 1.44B | PEG | - | EPS next Q | -0.76 | Inst Own | 69.6% | Short Float | 21.83% | Perf Quarter | 15.97% |
| Income | -0.13B | P/S | 89.57 | EPS this Y | 9.63% | Inst Trans | 12.59% | Short Ratio | 11.45 | Perf Half Y | 21.42% |
| Sales | 0.02B | P/B | 3.95 | EPS next 5Y | -5.85% | ROA | -31.99% | Short Interest | 7.53M | Perf YTD | -22.16% |
| Book/sh | 8.16 | P/C | 4.36 | EPS past 3/5Y | -0.41% - | ROE | -37.35% | 52W High | -39.89% ($53.65) | Perf Year | -2.98% |
| Cash/sh | 7.4 | P/FCF | - | Sales past 3/5Y | - | ROIC | -26.26% | 52W Low | 46.92% ($21.95) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -50.45% | Gross Margin | 90.47% | Volatility(W/M) | 4.28% 5.38% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 72.04 | Sales Y/Y TTM | 700% | Oper. Margin | -728.06% | ATR (14) | 1.63 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 18.31 | EPS Q/Q | 1.29% | Profit Margin | -667.95% | RSI (14) | 63.61 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 18.31 | Sales Q/Q | - | SMA20 | 8.76% ($29.65) | Beta | 2.06 | Target Price | $62.54 |
| Payout | - | Debt/Eq | 0.13 | Earnings | 2026/8/11 | SMA50 | 17% ($27.56) | Rel Volume | 0.74 | Prev Close | $30.37 |
| Employees | 141 | LT Debt/Eq | 0.12 | EPS/Sales Surpr. | -5.95% -100% | SMA200 | 1.54% ($31.76) | Avg Volume(3M) | 0.66M | Price | $32.25 |
| IPO | 2025/1/31 | Option/Short | Yes/Yes | Trades | 8114 | Volume | 488,841 | Change | 6.19% |
🧬 Maze Therapeutics (MAZE) is a US clinical-stage biotech company developing precision medicines based on human genetics data. It has oral small-molecule candidates targeting kidney and metabolic diseases and pursues an approach that leverages genetic insights to define well-defined patient populations.
Over the past 1 year, roughly in the middle
40% below its 1-year high.
Traded less than usual. That is 74% of its average volume.
MAZE has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +9.6% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $8,957. Peers typically go for $1,242.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
21.8% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #110 of 597 in the industry
Based on market cap of $2B.
FAQ
What kind of company is MAZE?
MAZE belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MAZE?
The market cap of MAZE is approximately $1.8B, ranking 2,140 within its sector.
What is the 52-week high and low for MAZE?
MAZE has recorded a 52-week high of $53.65 and a low of $21.95.
